Dazcapistat

Overview

Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 ( calpain 1, 2, 9 ). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis . Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung . Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis.

Application

Products | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Infection | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Pulmonary Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Proteasome | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-132850
• CAS No.: 2221010-42-8
• Molecular Formula: C21H18FN3O4
• Molecular Weight: 395.38
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
• Availability: In-stock

Source

Original product source